enVVeno Medical (NASDAQ:NVNO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of enVVeno Medical (NASDAQ:NVNO) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Several other equities analysts also recently commented on the company. LADENBURG THALM/SH SH raised enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of enVVeno Medical in a research report on Friday, September 25th. Finally, Zacks Research raised shares of enVVeno Medical to a “hold” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

enVVeno Medical Trading Down 3.8%

Shares of NASDAQ:NVNO opened at $6.65 on Friday. enVVeno Medical has a 12 month low of $6.55 and a 12 month high of $26.72. The company has a market capitalization of $4.59 million, a price-to-earnings ratio of -0.34 and a beta of 1.29. The firm’s 50-day moving average is $9.39 and its 200 day moving average is $10.30.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($5.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.69) by ($0.68). As a group, equities analysts forecast that enVVeno Medical will post -16.19 EPS for the current fiscal year.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ: NVNO) is a medical device company focused on developing bioprosthetic solutions for vascular and cardiovascular diseases. The company’s technologies are designed to address conditions for which existing medical and surgical treatments may be limited or ineffective.

Its lead product candidate is the VenoValve, an investigational surgically implanted tissue-based valve intended to treat chronic deep venous insufficiency, including symptoms associated with post-thrombotic syndrome.